Medincell SA
Research Medincell SA (MEDCL) on Bullrun: market cap EUR 893.48M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMEDCL
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 893.48M
- Financial periodFY2025
- RevenueEUR 25.54M
- Revenue growth178.8%
- Net income-EUR 18.44M
- Free cash flowEUR 17.81M
- Gross margin100.0%
Valuation Snapshot
latest market cap is EUR 893.48M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 25.54M | -EUR 18.44M | EUR 17.81M | 100.0% | -0.62 | EUR 59.04M | EUR 58.76M | -EUR 16.37M |
| FY2024 | EUR 9.16M | -EUR 25.04M | -EUR 13.11M | 100.0% | -0.86 | EUR 19.46M | EUR 58.96M | -EUR 40.82M |
| FY2023 | EUR 9.94M | -EUR 32.01M | -EUR 22.03M | 100.0% | -1.27 | EUR 6.47M | EUR 54.65M | -EUR 42.29M |
| FY2022 | EUR 4.09M | -EUR 24.81M | -EUR 23.34M | 100.0% | -1 | EUR 24.62M | EUR 47.49M | -EUR 13.37M |
| FY2021 | EUR 8.34M | -EUR 24.81M | -EUR 22.99M | 100.0% | -1 | EUR 24.62M | n/a | -EUR 13.37M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | EUR 893.48M | n/a | n/a | n/a |
About Medincell SA
MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder. It is also developing mdc-TJK, a subcutaneous injection that is in the NDA preparation stage for the treatment of schizophrenia in adults;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Medincell SA's market cap?
Medincell SA's market capitalization is EUR 893.48M.
What does Medincell SA do?
MedinCell S.A., a clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France. The company develops solutions based on BEPO, a long-acting injectable technology. It offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults and bipolar I disorder.